Monoclonal antibodies (MAbs) were produced against the G, M2 and N proteins of bovine ephemeral fever virus (BEFV) and 29 were selected for further study. Thirteen neutralizing MAbs were assigned to one conformation-independent and at least two conformation-dependent antigenic sites on the G protein by a competitive binding ELISA. The panel of MAbs were tested by neutralization and immunofluorescence with three strains of BEFV and three BEFV-related viruses. The results indicated that BEFV strains from different sources were not identical and that the M2 protein was the least variable of the proteins investigated. Passive protection studies in mice showed that the correlation between neutralizing titre and resistance to challenge was 0-85 (P < 0.001).
Introduction
Bovine ephemeral fever virus (BEFV) is an arthropodborne rhabdovirus which causes an acute and disabling inflammatory disease in cattle and water buffalo. The BEF virion consists of five structural proteins, which have been designated L (180K), G (81K), N (52K), M1 (43K) and M2 (29K) (P. J. Walker et al., unpublished results). The G protein is an N-glycosylated membrane protein that forms projections on the virion surface and which can be removed by treatment with trypsin or nonionic detergent (Della-Porta & Brown, 1979; P. J. Walker et al., unpublished results) . BEFV is structurally and serologically related to rabies virus (P. J. Walker et al., unpublished results; Calisher et al., 1989; Murphy et al., 1972) although the viruses differ in many properties including host range, tissue tropism and in the size of the G protein. In rabies virus, the G protein is the antigen which is thought to elicit and react with neutralizing antibody (Wiktor et al., 1973) . As many as six antigenic sites have been defined on the rabies virus glycoprotein (G protein) using neutralizing monoclonal antibodies (MAbs) Wiktor et al., 1983; Bunschoten et al., 1989) . MAbs have also been used to demonstrate antigenic variation in both the G and N proteins of rabies virus strains and rabies-related viruses (Flamand et al., 1980) .
In this study neutralizing MAbs were characterized and assigned to antigenic sites on the BEFV G protein on the basis of competitive binding assays and the role of neutralizing antibody in passive protection of mice was investigated. The cross-reactivity of neutralizing and non-neutralizing MAbs to three BEFV proteins was determined for three BEFV strains and three BEFVrelated viruses.
Methods
Viruses and cells. The BB7721 strain of BEFV, isolated in mice from the blood of an infected cow (Doherty et al., 1969) was used for the production and testing of MAbs. The BEFV strains CSIRO 42 and CSIRO 53 were isolated in mice from mosquitoes (Standfast et al., 1976) . Berrimah (BRM) virus strain DPP63, Kimberley (KIM) virus strain CSIRO 368 and Adelaide River (AR) virus strain DPP61 were isolated in BHK-21 tissue culture from healthy cattle (Gard et al., 1983 (Gard et al., , 1984 . All viruses were propagated in BHK-21 cells and plaque-purified in Veto cells.
Production of murine hybridomas. Two types of antigen were employed to generate BEFV antibodies in mice. The first was prepared from BEFV-infected suckling mouse brain, homogenized in a 10~ phosphate-buffered saline (PBS) suspension and centrifuged at 1000g; the supernatant was used as the inoculum. The second, purified BEF antigen, was prepared by a method to be described elsewhere, then treated with Triton X-100 to remove the G protein, centrifuged at 265 000 g, and the nucleocapsid pellet containing little or no G protein was used as the inoculum. Adult male BALB/c mice were injected intraperitoneally with 0-5 ml of a mixture of BEFV antigen and an equal volume of Freund's complete adjuvant. A similar inoculation was given 1 week later using Freund's incomplete adjuvant, followed by four intraperitoneal injections over the following 2 months using 0.5 ml of BEFV antigen and no adjuvant. The fusion was carried out 4 days after the final injection by a method based on that of K6hler & Milstein (1976) . Fusion between BEFV-immune spleen cells and P3-X63-Ag8-653 myeloma ceils (Kearney et aL, 1979) was induced with 50~ polyethylene glycol 1500 (w/v) in 75 mM-HEPES (Boehringer Mann-0000=9456 © 1990 SGM D. 11. Cybinski and others helm). Mouse peritoneal macrophages served as feeder layers in 24-96-well tissue culture plates. Supernatants were screened for BEFV specificity by using an immunofluorescence assay (IFA) and positive clones were subcloned by limiting dilution. High concentrations of IgG in ascites fluid were obtained by inoculating 106 to t07 hybrid cells intraperitoneally into BALB/c mice primed 1 to 3 weeks previously with 0.3 ml Pristane (2,6,10,14-tetramethylpentadecane) as described by Brodeur et al. (1984) . Ascites fluids were clarified, heat-inactivated at 56 °C for 30 min and stored at -20 °C.
Antibody testing. Hybridoma supernatants were screened using an indirect IFA which was described by Cybinski & Zakrzewski (1983) , and modified for use in 96-well fiat-bottomed tissue culture plates. Monolayers of Vero cells were inoculated with 500 TCID5o of BEFV. After a 22 h incubation at 37 °C in an atmosphere of 5 ~ CO2, the plates were rinsed with 50% acetone in PBS and then fixed for 30 min with 100 ~tl/well of 70~ acetone in PBS. Hybridoma supernatants were incubated in the wells for 30 rain at 37 °C, washed with PBS, then stained with fluorescein isothiocyanate-conjugated rabbit anti-mouse immunoglobulin (Dako) for 30 min at 37 °C. After washing again with PBS the plates were examined by fluorescent microscopy. The presence of IFA-positive antibodies to other viruses was detected in a similar manner.
Neutralization tests were carried out in Vero cells by a modification of the method described by Cybinski et al. (1978) using either undiluted hybridoma supernatant or ascites fluid in twofold dilutions in 96-weU microtitre plates and adding 100 TCIDso of test virus. Titres were expressed as the reciprocal dilution of ascites fluid that neutralized the virus in 50% of the wells. Polyclonal antibodies for use in crossneutralization tests were prepared in mice or rabbits as described by Sartorelli et al. (1966) and Cybinski & Zakrzewski (1983) .
Isotyping. Isotyping of antibodies was carried out using a mouse monoclonal isotyping kit (Commonwealth Serum Laboratories) which detects Ig heavy and light chains by means of a urease-labelled antiIfiouse Fab conjugate.
Purification of immunoglobulin.
MAbs were purified by affinity chromatograpby of ascites fluid using DEAE-Affigel Blue (Bio-Rad)
as described by Bruck et al. (1982) . Fractions were analysed by SDS-PAGE and IFA and those containing pure BEFV-specific IgG were pooled and concentrated by ultrafiltration using a Diaflo ultrafiltration membrane YM10 (Amicon), dialysed against 50~ glycerol in 20 miTris-HC1 and stored at -20 °C. The concentration of IgG was estimated by a method described by Redinbaugh & Campbell (1985) using a Bio-Rad y-globulin standard.
Competitive binding assay. Purified MAbs were dialysed against 100 mM-NaHCO3 pH 8.2 and diluted to approximately 1 mg/ml IgG. NHS-LC biotin (Pierce Chemicals) in DMSO was added as described by Gretch et al. (1987) and allowed to react at room temperature for 2 h; then the products were dialysed extensively against 0.02~ NaN3 in PBS and stored at 4 °C. ELISA plates were coated overnight at 4 °C with gradient-purified BEFV antigen. All subsequent incubations were conducted at room temperature. Unbound sites were first blocked with 1 ~ gelatin and then the plates were incubated with 10-fold dilutions of one MAb which had been adjusted to 100 ~g/ml IgG, followed by the addition of biotinylated antibody at a predetermined dilution (giving an absorbance of between 0.4 and 0-6), and incubation for 1 h. Streptavidinbiotinylated horseradish peroxidase complex (Amersham), diluted 1000-fold was added and incubated for 1 h, followed by the addition of the substrate 5-amino salicylic acid with 0-002% H20 2 . After 30 rain, the absorbance was measured in an ELISA reader (Titertek Multiskan MKll) using a 492 nm filter. The percentage competition was calculated using the formula [100(A-n)]/(A-B), where A is the absorbance in the absence of competitor, B is the absorbance in the presence of homologous antibody and n is the absorbance in the presence of competing antibody (Hughes et al., 1988) . Reactions were graded as competition (> 75 ~), partial competition (35 ~ to 75 %), noncompetition (-35~ to 34~) and enhancement (E) or negative competition (< -35%).
Mouse passive protection test. Litters of [ to 2 day old mice were inoculated intraperitoneally with 30 ~tl ascites fluid containing either neutralizing or non-neutralizing MAb. Control mice received no antibody. After 2 h, the mice were inoculated intracerebrally with 20 ~tl of 1000 50~ lethal doses of BEFV grown in mouse brain. The mice were examined daily for 14 days and deaths were recorded.
Results

Production and characterization of MAbs
Using antigen 1 (BEFV-infected suckling mouse brain) as the inoculum, 26 stable, MAb-producing hybridomas were obtained after cloning. The antigenic specificity, isotype and virus neutralizing ability of each clone is shown in Table 1 . By protein immunoblotting, 21 MAbs reacted with the virion glycoprotein (G) and five reacted with the matrix protein (M2). Nine of the G-protein specific antibodies reacted in immunoblots after treatment with SDS and 2-mercaptoethanol (2-ME) whereas 12 others reacted only in the absence of 2-ME. Thirteen of the G protein-specific MAbs were capable of neutralizing BEFV in tissue culture. Using antigen 2 (BEFV nucleocapsids) as inoculum, 79 MAb-producing hybrids were detected by IFA and these were mainly specific for the nucleoprotein (N). Six of 10 cloned hybrids were stable and three of these were selected for further characterization (Table 1) .
Competitive binding assays
Thirteen neutralizing MAbs were biotinylated and reciprocal competitive binding assays were performed to determine the topological relationship of antigenic sites. Table 2 shows a summary of the competitive binding assays from data obtained using excess competing antibody. The results indicate that there are at least three distinct antigenic sites on the BEFV G protein. All MAbs assigned to site G 1 reacted in immunoblots with antigen which had been treated with SDS and 2-ME. MAbs assigned to site G2, however, reacted with G protein only in the absence of 2-ME. The conformation of site G3 also appears to be altered by treatment with 2-ME. The four antibodies which bound to site G3 were assigned to two subsets, G3a and G3b. Antibodies within each subset competed strongly, whereas some antibodies in different subsets showed partial competition. The binding of biotinylated 8B6 was inhibited by seven heterologous competing antibodies on three antigenic sites. However, six of these showed inhibition only at high antibody concentrations (> 10 ~tg/ml).
Serological reactions of MAbs with BEFV-related viruses
Viruses analysed for cross-reactivity using polyclonal antibodies and MAbs were the BB7721 strain of BEFV, the insect isolate CSIRO 42 and CSIRO 53 and three other viruses which have been shown to be serologically related to BEFV (BRM, KIM and AR viruses) (Cybinski, 1987) . The serological relationship between BEF group viruses by neutralization tests using polyclonal antibodies is shown in Table 3 . KIM and AR viruses, although known to be related by IFA (Gard et al., 1984) failed to cross-react in neutralization tests. Strong crossreactions were detected between BEFV and weaker cross-reactions were detected between BEFV strains and BRM virus. Two ascitic fluids prepared against BRM virus varied significantly in their patterns of crossreactivity with BEFV strains. The results of neutralization and IFA tests on neutralizing MAbs, using the same BEF group viruses, are shown in Table 4 . The results obtained by neutralization tests on ascites fluid generally agreed with those obtained by IFA on hybridoma supernatants with the exception of two antibodies reacting with epitopes in site G3 (8B6 and 8D3), which had low neutralizing titres and low IgG concentrations. Four of the antibodies which recognize -13A3  1024  3072  1024  <2  <2  <2  +  +  +  -17B1  1024  2048  1024  <2  <2  <2  +  +  +  -9C5  128  384  128  96  <2  <2  +  +  +  +  1C6  256  256  384  128  <2  <2  +  +  +  +  12A5  256  512  512  24  <2  <2  +  +  +  +  15B5  512  256  512  t28  <2  <2  +  +  +  +  llD1  4  16  8  8  <2  <2  +  +  +  +  3D6  512  256  <2  <2  <2  <2  +  +  --8B6  16  6  <2  <2  <2  <2  +  ---16A6  8  16  8  8  <2  <2  +  +  +  +  8D3  8  <2  8  8  <2 The virus specificity of non-neutralizing antibodies against three BEFV proteins using IFA is shown in Table 5 . Antibodies against the M2 protein were the most cross-reactive. One of the G protein-specific antibodies (3A2) reacted with all six viruses.
Protection studies in mice
The average survival time, in days, of suckling mice inoculated with ascites fluid containing MAb, 2 h prior to challenge with BEFV, is shown in Table 6 . For mice inoculated with neutralizing G protein-specific antibodies, the average survival time ranged from 5.3 to more than 14 days. The average survival time of the control mice was 4.7 days whereas that of the mice inoculated with eight non-neutralizing antibodies reacting with the G and M2 proteins was between 5.0 and 5.5 (data not shown) and these were not significantly different. A correlation of 0.84 (P < 0-001) was obtained between the tissue culture neutralization titres and the survival time in mice. In the case of five antibodies, some mice remained alive after 14 days when the experiment was terminated. For statistical purposes the survival time of these was estimated to be 16 days.
Discussion
In this study, MAbs produced using BEF mouse brain virus as inoculum, were predominantly specific for the BEFV G protein (80%) whereas 20% reacted with the M2 protein. The (3 protein of BEFV is known to be located mainly on the virion surface (P. J. Walker et al., unpublished results) and is therefore a target for antibodies. Antibodies to the N protein, a major BEFV protein, were not detected. However, when BEFV nucleocapsid antigen was used as inoculum, MAbs directed against the N protein predominated. Of the G protein-specific antibodies, 62~ were neutralizing, whereas all of the M2 and N reactive antibodies were non-neutralizing. This is consistent with previous studies which have demonstrated that virus-neutralizing antibodies are induced solely by the G protein of rabies virus (Wiktor et al., 1973) . Of the 21 G protein-reactive antibodies, 12 reacted in immunoblots only in the absence of 2-ME, indicating that the antigenic determinants are conformation-dependent. The remaining nine antibodies reacted with antigen denatured by 2-ME, suggesting that these epitopes may consist of sequential determinants or of regions whose conformation is not readily altered by 2-ME. Most of the 29 MAbs described here were shown to be unique by comparing isotypes, cross-reactivity by neutralization and IFA, protein specificity and competitive binding reactions. However, the possibility cannot be ruled out that the few antibodies with similar properties (e.g. 1C6 and 15B5) might, be siblings. At least 12 distinct epitopes were defined by the 13 BEFV neutralizing MAbs which were investigated serologically and by using competitive binding assays. Further information on the topographical arrangement of these epitopes, provided by competitive binding assays, indicated that certain epitopes were either overlapping or in close proximity, and that these could be grouped into at least three distinct antigenic sites. Antibodies to two of these sites (G1 and G2) were easily distinguished, whereas antibodies to the third site fell into two subgroups, designated G3a and G3b, with greater binding inhibition occurring within each subgroup than between the subgroups. Five neutralizing antibodies in this study bound antigen in the presence of denaturing agents in immunoblots. All five reacted with antigenic site G1, suggesting that this site is conformation-independent and may consist of a linear sequence of amino acids. Sequence data are necessary to confirm this. All MAbs specific for antigenic sites G2 and G3 reacted in immunoblots only in the absence of 2-ME, suggesting that disulphide bonds were necessary for the native conformation of these sites. Antigenic mapping of the G protein of the CVS strain of rabies virus has defined three neutralizing sites, and five neutralizing sites have been demonstrated for the ERA strain G protein of rabies virus Wiktor et al., 1983) . These sites were reported to be conformationdependent. An additional conformation-independent neutralizing site has been found by Bunschoten et al. (1989) using the Pitman-Moore strain of rabies virus, but this site was also shown to be present on the CVS and ERA strains. Some MAbs were able to enhance the binding of antibodies on other antigenic sites. This phenomenon has been described for bovine herpesvirus type 1 glycoprotein IV (Hughes et al., 1988) and for the envelope protein of Japanese encephalitis virus (Cecilia et al., 1988) . Although enhancement of antibody binding may be a natural occurrence, it may also be caused by changes in antigen conformation produced during preparation of the antigen or when coating the ELISA plate. These conformational changes may interfere with antibody binding while the binding of certain antibodies may restore or partially restore the native conformation. It is interesting to note that the same antibodies which caused binding enhancement of biotinylated 16A6 inhibited binding of biotinylated 8B6 at high concentrations. Observations such as these highlight the importance of antigen conformation and suggest that the binding of antibody to some epitopes can influence binding to epitopes which are not necessarily in close proximity.
All MAbs were prepared using the BB7721 strain of BEFV. Other BEF group viruses available for comparison were BRM, KIM and AR viruses and the insect isolates of BEFV, CSIRO 42 and CSIRO 53. Using polyclonal antisera in the neutralization test, it was possible to distinguish easily between KIM and AR viruses and the other four viruses. CSIRO 42 and CSIRO 53 viruses were not identical to BEFV, but showed strong cross-reactivity. BRM and BEF viruses were shown to cross-react either in one direction, as described by Gard et al. (1983) , or in both directions, depending on the ascitic fluid used, demonstrating the difficulty often experienced when using polyclonal antisera to identify closely related viruses. It has been reported by Snowdon (1970) that antigenic differences could not be detected between field isolates of BEFV obtained from different sources, using serological methods available at that time. The results here show that two BEFV isolates from insects were distinguishable from the BB7721 strain using MAbs, although CSIRO 42 was very closely related with only three of 29 BEFV antibodies failing to recognize this virus. To summarize the IFA results of Tables 4 and 5 , of 29 MAbs reacting with the BB7721 strain of BEFV, 26 reacted with the CSIRO 42 strain and 21 reacted with the CSIRO 53 strain of BEFV. Fourteen reacted with BRM virus, eight with KIM virus and only five with AR virus. The neutralizing MAbs assigned to antigenic site G1 were mainly BEFV strain-specific. Those recognizing site G2 all neutralized BEFV strains and BRM virus, although the lower titre for 12A5 with BRM virus indicates that this epitope is not identical to the epitope in the BEFV strains. The MAbs assigned to antigenic site 3a did not neutralize CSIRO 53 whereas those assigned to site G3b were more cross-reactive. This panel of MAbs to BEFV, which can distinguish strainspecific, BEFV-specific and cross-reactive epitopes, is valuable as a diagnostic tool to facilitate strain differentiation. There is also a potential use in differentiating pathogenic from non-pathogenic BEF group viruses. If more than one pathogenic strain exists, MAbs may be used in the characterization of peptides for potential vaccines and in the investigatiGn of any failure which may occur in currently available vaccines. Using MAbs, BEFV-specific ELISAs have been developed which will detect both antibody and antigen (H. Zakrzewski, unpublished data).
MAbs to different BEFV proteins varied in the extent of their cross-reactivity with BEF group viruses. In general, antigenic determinants which were present on the BEFV G protein (as defined by MAbs) were absent in AR and KIM viruses. There were two exceptions defined by 3A2, a non-neutralizing antibody which reacted with all the viruses tested, and 8D3, a neutralizing antibody which reacted with KIM virus by IFA only. BEF and BRM viruses shared 409/0 of the antigenic determinants on the G protein. The limited information available suggests that BEF group viruses share more antigenic determinants on the M2 and N proteins than on the G protein, and that the M2 protein is antigenically the most cross-reactive of the three proteins examined. If the M2 protein is the least variable of these proteins it may be responsible for much of the cross-reactivity observed with polyclonal antibodies by IFA.
Although BEF disease has not been reproduced in small animals, suckling mice are readily infected when inoculated intracerebrally, and so provide a convenient indicator of the presence of BEFV. Pretreatment of suckling mice with neutralizating MAbs offered varying degrees of protection to subsequent challenge with BEFV. In a number of cases, the mice survived longer than the 14 days at which the experiment was terminated, whereas control mice and those inoculated with non-neutralizing MAbs survived only between 4-7 and 5.5 days. The correlation coefficient of 0.84 (P < 0.001) obtained between the tissue culture neutralization titres and the survival time was highly significant and this indicates that, in mice at least, neutralizing antibody can be protective and that protection correlates with neutralizing titre. In contrast, Della-Porta & Snowdon (1979) reported that resistance to challenge is independent of neutralizing titre in cattle. Other factors may also play a role in protection, and it remains to be seen whether or not the passive protection results in mice can be reproduced in cattle. The possible existence of a linear neutralizing antigenic site which apparently elicits antibodies protective for mice offers some hope of a subunit BEFV vaccine in the future.
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